Background: Mavacamten was approved by the US Food and Drug Administration (FDA) in April 2022 for the treatment of adults with New York Heart Association (NYHA) class II-III symptomatic obstructive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback